About ART

ART’s proprietary, platform technology has led to the development of two market-ready products, two clinical stage products and a multitude of pipeline products. With its portfolio of near- and long-term assets, ART offers a broad product line based on its exclusive resin-based technology.  ART’s first market-ready product is out-licensed and NicoSwab™ is set to launch in 2016.